Treatment of acute myeloid leukemia developing after a myelodysplastic phase with low dose arabinosyl cytosine
- 31 December 1985
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 9 (10) , 1293-1298
- https://doi.org/10.1016/0145-2126(85)90159-6
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The effect of low dose Ara‐C in acute non‐lymphoblastic leukaemias and atypical leukaemiaBritish Journal of Haematology, 1984
- CYTARABINE IN PRE-LEUKAEMIAThe Lancet, 1984
- Clinical trial of low-dose Ara-C in the treatment of acute leukemia and myelodysplasiaAnnals of Hematology, 1984
- Low-dose cytosine-arabinoside in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)Annals of Hematology, 1984
- Cell differentiation and therapeutic effect of low doses of cytosine arabinoside in human myeloid leukemiaLeukemia Research, 1984
- Response of Preleukemic Syndromes to Continuous Infusion of Low-Dose CytarabineNew England Journal of Medicine, 1983
- Treatment of acute myelocytic leukemia with low-dose cytosine arabinoside: Results of a pilot study in four patientsLeukemia Research, 1983
- Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemiaLeukemia Research, 1983
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982
- Small doses of ARA-C in the treatment of acute myeloid leukaemia: differentiation of myeloid leukaemia cells?British Journal of Haematology, 1982